FrancophonIA/ELRC3.0 huggingface dataset:
English: What Ilaris looks like and contents of the pack Ilaris is supplied as a powder for solution for injection (150 mg in a 6 ml glass vial).
Estonian: Ilaris on süstelahuse pulber (150 mg 6 ml klaasist viaalis).
English: It is unknown whether canakinumab is excreted in human milk.
Estonian: Ei ole teada, kas kanakinumab eritub inimese rinnapiima.
English: If full treatment response after 7 days, maintenance dose: 600 mg or 8 mg/kg every 8 weeks
Estonian: Kui 7 päeva järel saavutatakse täielik ravivastus, tuleb jätkata säilitusannusega: 600 mg või 8 mg/kg iga 8 nädala järel
English: Ilaris 150 mg powder for solution for injection is supplied in a single-use vial for individual use.
Estonian: Ilaris 150 mg süstelahuse pulber on pakendatud üksikannustena viaalidesse ühekaupa kasutamiseks.
English: INSTRUCTIONS ON USE
Estonian: Manustamise juhised
English: Phase III trial, pivotal, randomised placebo-controlled treatment period (Part II) Canakinumab n/N (%)
Estonian: III faasi uuringu keskne platseebokontrolliga raviperiood (II osa) Kanakinumab n/N (%)
English: If you have CAPS, TRAPS, HIDS/MKD, FMF or Still's disease (AOSD or SJIA), you may inject yourself with Ilaris after proper training, or a caregiver may inject it for you.
Estonian: Kui teil on CAPS, TRAPS, HIDS/MKD, FMF või Stilli tõbi (täiskasvanu eas alanud Stilli tõbi või SJIA), võite te Ilarist endale ise süstida pärast õpetuse saamist või süstib teid hooldaja.
English: Maintenance dose 4 mg/kg every 8 weeks
Estonian: Säilitusannus 4 mg/kg iga 8 nädala järel
English: Stopping your treatment with Ilaris may cause your condition to get worse.
Estonian: Kui te ravi Ilarisega lõpetate, võib haigus süveneda.
English: Triglycerides
Estonian: Triglütseriidid
English: Canakinumab also demonstrated superior efficacy compared to placebo on the secondary endpoints of PGA < 2 and CRP ≤ 10 mg/l in all three cohorts.
Estonian: Kõigis kolmes kohordis olid ka teisesed tulemusnäitajad, PGA < 2 ja CRP ≤ 10 mg/l, kanakinumabiga paremad kui platseebo korral.
English: Treatment with canakinumab should not be initiated in patients with neutropenia or leukopenia.
Estonian: Neutropeenia või leukopeeniaga patsientidel ei tohi kanakinumabiga ravi alustada.
English: Mean values for Cmax and AUCinf after a single subcutaneous dose of 150 mg in a typical adult CAPS patient (70 kg) were 15.9 µg/ml and 708 µg*d/ml.
Estonian: Pärast ühekordset subkutaanset 150 mg annust olid keskmisel CAPS patsiendil (70 kg) Cmax ja AUCinf 15,9 mikrogrammi/ml ja 708 mikrogrammi*d/ml.
English: Paediatric patients:
Estonian: Eakad patsiendid
English: Laboratory abnormalities in TRAPS, HIDS/MKD and FMF patients Neutrophils
Estonian: Kõrvalekalded laboratoorsete analüüside tulemustes TRAPSi, HIDSi/MKD ja FMFi patsientidel Neutrofiilid
English: Therefore patients should be monitored carefully for signs and symptoms of infections during and after treatment with canakinumab.
Estonian: Seetõttu tuleb patsiente ravi ajal ja pärast ravi kanakinumabiga hoolikalt jälgida infektsiooninähtude suhtes.
English: Physician Global Assessment < 2
Estonian: PGA < 2
English: The solution is clear to opalescent and colourless to slightly brownish yellow.
Estonian: Süstelahus on selge kuni opalestseeruv ning värvitu kuni kergelt pruunikaskollane.
English: For the primary efficacy endpoint, canakinumab was superior to placebo for all three disease cohorts.
Estonian: Kõigis kolmes kohordis oli esmane tulemusnäitaja kanakinumabiga parem kui platseebo korral.
English: Dispose of it as directed by your healthcare provider or pharmacist.
Estonian: Hävitage see vastavalt tervishoiutöötajalt või apteekrilt saadud juhistele.
English: Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF).
Estonian: Perekondlik Vahemere palavik (familial Mediterranean fever, FMF) Ilaris on näidustatud perekondliku Vahemere palaviku raviks.
English: Gently push the plunger all the way down until all of the air is injected into the vial.
Estonian: Vajutage kolb ettevaatlikult alla, kuni kogu õhk on viaali süstitud.
English: A 56-week, open-label study was conducted to assess the efficacy, safety and tolerability of canakinumab in paediatric CAPS patients ≤ 4 years of age.
Estonian: Kanakinumabi efektiivsust, ohutust ja taluvust ≤ 4-aastastel CAPS diagnoosiga patsientidel uuriti56-nädalases avatud uuringus.
English: The recommended dose of canakinumab for patients with Still's disease (AOSD and SJIA) with body weight ≥ 7.5 kg is 4 mg/kg (up to a maximum of 300 mg) administered every four weeks via subcutaneous injection.
Estonian: Stilli tõbi (täiskasvanu eas alanud Stilli tõbi ja SJIA) Kanakinumabi soovitatav annus kehakaaluga ≥ 7,5 kg Stilli tõvega (täiskasvanu eas alanud Stilli tõbi ja SJIA) patsientidel on 4 mg/kg (maksimaalselt 300 mg) manustatuna iga nelja nädala järel subkutaanse süstena.
English: Drop in level of white blood cells which help prevent infection (neutropenia).
Estonian: Infektsioonide eest kaitsvate vere valgeliblede arvu vähenemine (neutropeenia) Triglütseriidide ebanormaalne tase veres (rasvade ainevahetuse häire).
English: An additional pharmacokinetics analysis showed that the pharmacokinetics of canakinumab in 6 paediatric CAPS patients under the age of 2 years were similar to the pharmacokinetics in paediatric patients 2-4 years of age.
Estonian: Täiendav kanakinumabi farmakokineetika analüüs 6 CAPS diagnoosiga alla 2-aastasel lapsel näitas, et farmakokineetika on sarnane lastega vanuses 2...4 aastat.
English: For maximum effect, canakinumab should be administered as soon as possible after the onset of a gouty arthritis attack.
Estonian: Maksimaalse toime saamiseks tuleb kanakinumabi manustada võimalikult kiiresti pärast podagrahoo algust.
English: Take off the protective cap from the Ilaris vial.
Estonian: Eemaldage Ilarise viaalilt kate.
English: There was no indication of accelerated clearance or time-dependent change in the pharmacokinetic properties of canakinumab following repeated administration.
Estonian: Korduva manustamise järgselt ei täheldatud kliirensi kiirenemist ega kanakinumabi farmakokineetiliste parameetrite ajast sõltuvat muutust.
English: Read all the way through these instructions before injecting.
Estonian: Lugege see juhend lõpuni, enne kui alustate ravimi süstimist.
English: If a satisfactory clinical response has not been achieved 7 days after treatment start, a second dose of canakinumab at 150 mg or 2 mg/kg can be considered.
Estonian: Kui patsientidel ei ole 7 päeva pärast ravi alustamist saavutatud kliinilist ravivastust, võib kaaluda kanakinumabi teise 150 mg või 2 mg/kg annuse manustamist.
English: Open the wrapper containing the injection needle and attach the needle to the syringe.
Estonian: Avage süstenõela sisaldav pakend ja kinnitage nõel süstla külge.
English: If you have any questions, talk to your doctor, pharmacist or nurse.
Estonian: Küsimuste korral rääkige oma arsti, apteekri või meditsiiniõega.
English: If full treatment response after 7 days, maintenance dose: 8 mg/kg every 8 weeks
Estonian: Kui 7 päeva järel saavutatakse täielik ravivastus, tuleb jätkata säilitusannusega: 8 mg/kg iga 8 nädala järel
English: Ilaris is injected every 8 weeks as a single dose.
Estonian: Ilarist süstitakse ühekordse annusena iga 8 nädala järel.
English: • 4 mg/kg for patients who weigh between 7.5 kg and less than 15 kg - Children aged 2 or 3 years
Estonian: • 4 mg/kg patsientidele, kes kaaluvad vähemalt 7,5 kg kuni15 kg - 2 kuni 3 aasta vanused lapsed:
English: • 4 mg/kg for patients with body weight ≥ 7.5 kg
Estonian: • 4 mg/kg patsientidele kehakaaluga vähemalt 7,5 kg
English: Clean the injection site with a new alcohol swab.
Estonian: Puhastage süstekoht uue alkoholitampooniga.
English: After reconstitution, each ml of solution contains 150 mg canakinumab.
Estonian: Pärast lahustamist sisaldab lahuse iga ml 150 mg kanakinumabi.
English: If you respond well enough to the third dose, your treatment will be continued at 600 mg or 8 mg/kg every 8 weeks.
Estonian: - Kui te pärast kolmanda annuse manustamist saavutate piisava ravivastuse, jätkatakse teie ravi annusega 600 mg või 8 mg/kg iga 8 nädala järel.
English: Continued treatment with canakinumab in patients without clinical improvement should be reconsidered by the treating physician.
Estonian: Kliinilise paranemiseta patsientidel peab raviarst uuesti hindama kanakinumabi ravi jätkamist.
English: Bioavailability in gouty arthritis patients has not been determined independently.
Estonian: Podagraga patsientide hulgas ei ole iseseisvalt biosaadavust määratud.
English: Do not touch the vial stopper.
Estonian: Ärge puudutage viaali korki.
English: Laboratory abnormalities in gouty arthritis patients Haematology
Estonian: Kõrvalekalded laboratoorsete analüüside tulemustes podagraga patsientidel Hematoloogia
English: Also contains: sucrose, histidine, histidine hydrochloride monohydrate, polysorbate 80.
Estonian: Sisaldab ka: sahharoosi, histidiini, histidiinvesinikkloriidmonohüdraati, polüsorbaat 80.
English: Immediately proceed to administering the injection.
Estonian: Alustage koheselt süstimisega.
English: Upper abdominal pain.
Estonian: Süstelahuse pulber.
English: Non-clinical data reveal no special hazard for humans based on conventional studies of crossreactivity, repeated dose toxicity, immunotoxicity, toxicity to reproduce and development.
Estonian: Ristreaktiivsuse, korduvtoksilisuse, immunotoksilisuse, reproduktsiooni- ja arengutoksilisuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: Platelets
Estonian: Süstimine
English: Ilaris is injected every 4 weeks as a single dose.
Estonian: Ilarist süstitakse ühekordse annusena iga 4 nädala järel.
English: Laboratory abnormalities in SJIA patients
Estonian: Kõrvalekalded laboratoorsete analüüside tulemustes SJIA patsientidel Hematoloogia
English: The other ingredients are mannitol, histidine, histidine hydrochloride monohydrate, polysorbate 80, water for injections.
Estonian: Teised koostisosad on mannitool, histidiin, histidiinvesinikkloriidmonohüdraat, polüsorbaat 80, süstevesi.
English: Keep the vial in the outer carton in order to protect from light.
Estonian: Viaal hoida välispakendis, valguse eest kaitstult.
English: Additional dose of 4 mg/kg can be considered
Estonian: Võib kaaluda teise 4 mg/kg annuse manustamist
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Estonian: Kuidas Ilaris välja näeb ja pakendi sisu
English: Decreases in absolute neutrophil counts (ANC) to less than 1 x 10
Estonian: Kogu SJIA programmi käigus teatati mööduvast neutrofiilide absoluutarvu (ANC) vähenemisest alla 1 x 10
English: Gently push the plunger all the way down until air is in the vial.
Estonian: Vajutage kolb ettevaatlikult lõpuni alla, kuni õhk on viaalis.
English: - Keep the vial in the outer carton in order to protect from light.
Estonian: - Viaal hoida välispakendis valguse eest kaitstult.
English: Additional dose of 2 mg/kg can be considered
Estonian: Võib kaaluda teise 2 mg/kg annuse manustamist
English: • 4 mg/kg for patients with body weight ≥ 7.5 kg and < 15 kg Children 2 to < 4 years of age:
Estonian: • 4 mg/kg patsientidele, kes kaaluvad 7,5 kg kuni 15 kg - 2 kuni 3 aasta vanused lapsed:
English: Asymptomatic and mild elevations of serum bilirubin have been observed in CAPS patients treated with canakinumab without concomitant elevations of transaminases.
Estonian: Ilarisega ravitud CAPS patsientidel on täheldatud seerumi bilirubiinisisalduse asümptomaatilist ja vähest suurenemist ilma maksa aminotransferaaside aktiivsuse kaasuva suurenemiseta.
English: The recommended dose of Ilaris for adult gouty arthritis patients is 150 mg given as a single dose at the time of a gouty arthritis attack.
Estonian: Soovituslik Ilarise annus täiskasvanud podagraga patsientidel on 150 mg üksikannusena manustatuna podagrahoo ajal.
English: Also contains: mannitol, histidine, histidine hydrochloride monohydrate, polysorbate 80, water for injections.
Estonian: Sisaldab ka: mannitool, histidiin, histidiinvesinikkloriidmonohüdraat, polüsorbaat 80, süstevesi.
English: One vial contains 150 mg of canakinumab*.
Estonian: Üks viaal sisaldab 150 mg kanakinumabi* (canakinumabum).
English: one 27 G x 0.5 inch (or similar, as available on the market) needle for injecting (“injection needle”) alcohol swabs clean, dry cotton swabs an adhesive plaster a proper disposal container for used needles, syringe and vial (sharps container)
Estonian: Pakendis ei ole: - üks 1,0 ml süstal - üks nõel (näiteks 18 G või 21 G x 2-tolline või sarnane, mis on saadaval) lahuse võtmiseks viaalist („lahuse võtmise nõel“) - üks 27 G x 0,5-tolline (või sarnane, mis on saadaval) nõel süstimiseks (“süstenõel”) - alkoholitampoonid - puhtad, kuivad vatitupsud - plaaster - sobiv konteiner kasutatud nõelade, süstla ja viaali hävitamiseks (teravate esemete konteiner)
English: Recap the transfer needle as instructed by your healthcare provider or pharmacist.
Estonian: Asetage tagasi ülekandenõela kate, nagu on juhendanud tervishoiutöötaja või apteeker.
English: Properly dispose of vials containing remaining water and Ilaris solution (if any) as directed by your healthcare provider or pharmacist.
Estonian: Hävitage alles jäänud vett või Ilarise lahust sisaldavad viaalid vastavalt tervishoiutöötajalt või apteekrilt saadud juhistele.
English: Remove the syringe and withdrawal needle from the vial.
Estonian: Eemaldage süstal ja lahuse võtmise nõel viaalist.
English: Powder for solution for injection in a vial (type I glass) with a stopper (coated chlorobutyl rubber) and flip-off cap (aluminium).
Estonian: Süstelahuse pulber (kaetud klorobutüülkummist) korgi ja (alumiiniumist) äratõmmatava sulguriga viaalis (I tüüpi klaasist viaal).
English: Remove the transfer needle from the syringe.
Estonian: Eemaldage ülekandenõel süstla küljest.
English: Efficacy results in a subgroup of patients unable to use both NSAIDs and colchicine and who were on ULT, failed ULT or had a contraindication to ULT (N=101) were consistent with the overall study population with a statistically significant difference compared to triamcinolone acetonide in pain intensity at 72 hours (-10.2 mm, p=0.0208) and in reduction of risk of subsequent attacks (Hazard ratio 0.39, p=0.0047 at 24 weeks).
Estonian: Valu intensiivsuse erinevus 72 tunni möödudes võrreldes triamtsinoloonatsetoniidiga (-10,2 mm, p=0,0208) ning järgnevate hoogude esinemise riski vähenemine (Riski suhe 0,39, p=0,0047 24 nädala möödudes) oli statistiliselt oluline.
English: Your doctor may check whether you have tuberculosis using a specific test. if you have signs of a liver disorder such as yellow skin and eyes, nausea, loss of appetite, darkcoloured urine and light-coloured stools.
Estonian: kui teil esineb maksatalitluse häire nähud, nagu naha ja silmavalgete kollasus, iiveldus, isutus, tumedat värvi uriin või heledat värvi väljaheide.
English: Solution for injection in a vial (type I glass) with a stopper (laminated chlorobutyl rubber) and flip-off cap (aluminium).
Estonian: Süstelahus (lamineeritud klorobutüülkummist) korgi ja (alumiiniumist) äratõmmatava sulguriga viaalis (I tüüpi klaasist viaal).
English: Ilaris 150 mg/ml injection canakinumab SC
Estonian: Ilaris 150 mg/ml süstelahus canakinumabum s.c.
English: Remove the syringe and needle from the vial.
Estonian: Võtke süstal ja lahuse võtmise nõel ümbrisest välja.
English: • 2 mg/kg for patients who weigh between 7.5 kg and less than 40 kg
Estonian: • 2 mg/kg patsientidele, kes kaaluvad 7,5 kg kuni 40 kg
English: GENERAL CLASSIFICATION FOR SUPPLY
Estonian: Süstimiseks ettevalmistumine
English: If a full treatment response is subsequently achieved, the intensified dosing regimen of 300 mg or 4 mg/kg every 8 weeks should be maintained.
Estonian: Kui selle tulemusena saavutatakse täielik ravivastus, tuleb ravi jätkata suurema annusega: 300 mg või 4 mg/kg iga 8 nädala järel.
English: Tumour necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) and familial Mediterranean fever (FMF) The recommended starting dose of Ilaris is: - Adults and children aged 2 years or more
Estonian: Tuumori nekroosi faktori retseptoriga seotud perioodilised sündroomid (TRAPS), hüperimmunoglobuliin D sündroom (HIDS)/mevalonaadi kinaasi puudulikkus (MKD) ja perekondlik Vahemere palavik (FMF)
English: Ilaris 150 mg powder for solution for injection
Estonian: Ilaris 150 mg süstelahuse pulber
English: If you see bubbles in the syringe, remove bubbles as instructed by your healthcare professional or pharmacist.
Estonian: Kui näete süstlas mulle, eemaldage need vastavalt tervishoiutöötajalt või apteekrilt saadud juhistele.
English: If you do not respond well enough to the second dose, a third dose of Ilaris at 300 mg or 4 mg/kg may be given.
Estonian: - Kui te ei saavuta pärast teise annuse manustamist piisavat ravivastust, võib arst kaaluda teile kolmanda Ilarise 300 mg või 4 mg/kg annuse manustamist.
English: - Any unused medicine must be discarded after withdrawal of the dose.
Estonian: - Kohe pärast süste tegemist tuleb kasutamata jäänud lahus ära visata.
English: Instructions for use of Ilaris solution for injection
Estonian: Ilaris süstelahuse kasutusjuhend
English: One vial of powder contains 150 mg canakinumab.
Estonian: Üks pulbri viaal sisaldab 150 mg kanakinumabi.
English: Common features of AOSD and SJIA include fever, rash, hepatosplenomegaly, lymphadenopathy, polyserositis and arthritis.
Estonian: Sagedaseimad täiskasvanu eas alanud Stilli tõve ja SJIA nähud on palavik, lööve, hepatosplenomegaalia, lümfadenopaatia, polüserosiit ja artriit.
English: Concomitant treatment with ULTs was reported by 42% of patients at entry.
Estonian: 42% patsientidest said uuringu alguses kaasuvana hüperurikeemiavastast ravi.
English: Pull the plunger all the way down to the 1.0 ml mark, filling the syringe with air. Insert the needle into the water vial through the centre of the rubber stopper.
Estonian: Tõmmake süstla kolb tagasi 1,0 ml tähiseni, täites süstla õhuga.
English: If you respond well enough to the second dose, your treatment will be continued with 300 mg or 4 mg/kg every 8 weeks.
Estonian: - Kui te pärast teise annuse manustamist saavutate piisava ravivastuse, jätkatakse teie ravi annusega 300 mg või 4 mg/kg iga 8 nädala järel.
English: Ilaris 150 mg powder for solution for injection canakinumab
Estonian: Ilaris 150 mg süstelahuse pulber canakinumabum
English: Drop in level of blood cells which help prevent bleeding (platelets).
Estonian: Veritsuse eest kaitsvate vererakkude (trombotsüüdid) arvu vähenemine.
English: Slowly inject the water into the vial containing the Ilaris powder.
Estonian: Süstige 1,0 ml vett aeglaselt Ilarise pulbrit sisaldavasse viaali.
English: TRAPS, HIDS/MKD and FMF: Adults, adolescents and children aged 2 years and older The recommended starting dose of canakinumab in TRAPS, HIDS/MKD and FMF patients is:
Estonian: TRAPS, HIDS/MKD ja FMF: Täiskasvanud, noorukid ja lapsed alates 2 aasta vanusest Kanakinumabi soovitatav algannus TRAPSi, HIDSi/MKD ja FMFi patsientidele: 150 mg patsientidele kehakaaluga > 40 kg 2 mg/kg patsientidele kehakaaluga ≥ 7,5 kg ja ≤ 40 kg
English: Keep your doctor informed of your condition and any symptoms before you use or are given Ilaris (see section 2).
Estonian: Teavitage arsti oma seisundist ja kõigist haigusnähtudest enne kui te kasutate või teile manustatakse Ilarist (vt lõik 2).
English: Recap the withdrawal needle as instructed by your healthcare provider or pharmacist.
Estonian: Asetage tagasi lahuse võtmise nõela kate, nagu on juhendanud tervishoiutöötaja või apteeker.
English: Peak concentrations of canakinumab occurred between 2 to 7 days (Tmax) following single subcutaneous administration of canakinumab 150 mg or 2 mg/kg in paediatric patients 4 years of age and older.
Estonian: 4-aastasetel ja vanematel lastel saabus kanakinumabi maksimaalne kontsentratsioon 2...7 päeva (Tmax) pärast 150 mg või 2 mg/kg ühekordset subkutaanset manustamist.
English: There were 102 TRAPS, HIDS/MKD and FMF patients (2-17 years of age) who received canakinumab in a 16-week study.
Estonian: 16 nädalat kestnud uuringus raviti kanakinumabiga 102 TRAPS, HIDS/MKD ja FMF diagnoosiga last (vanuses 2...17 aastat).
English: - Put the withdrawal needle on the syringe.
Estonian: - Kinnitage lahuse võtmise nõel süstlale.
English: Patients must be monitored closely for signs and symptoms of tuberculosis during and after treatment with canakinumab.
Estonian: Kanakinumabiga ravi ajal ja pärast ravi tuleb patsiente hoolikalt jälgida tuberkuloosi nähtude ja sümptomite suhtes.
English: It was estimated to be 0.17 l/d in a CAPS patient of body weight 70 kg and 0.11 l/d in a SJIA patient of body weight 33 kg. After accounting for body weight differences, no clinically significant differences in the pharmacokinetic properties of canakinumab were observed between CAPS and SJIA patients.
Estonian: Hinnanguliselt on see 70 kg kaaluval CAPS patsiendil 0,17 l/d ja 33 kg kaaluval SJIA patsiendil 0,11 l/d.
English: Ilaris has not been studied in patients with hepatic impairment.
Estonian: Maksakahjustusega patsientidel ei ole Ilarise kasutamist uuritud.
English: One vial contains 150 mg canakinumab.
Estonian: Üks viaal sisaldab 150 mg kanakinumabi.
English: Avoid touching the needles and the tops of the vials.
Estonian: Ärge puutuge nõelu ega viaalide ülaosa.
English: Do not rub the injection area.
Estonian: Ärge süstekohta hõõruge.
English: In clinical studies, canakinumab has been safely administered with ULT.
Estonian: Kusihappetaset vähendavat ravi (ULT) saavad patsiendid Kliinilistes uuringutes on kanakinumabi ohutult manustatud koos ULT-ga.
English: Insert the needle all the way into the vial until it reaches the bottom edge.
Estonian: Lükake nõel kuni viaali põhjani.
English: If a full treatment response is subsequently achieved, maintaining the intensified dosing regimen of 8 mg/kg every 8 weeks should be considered, based on individual clinical judgement.
Estonian: Kui selle tulemusena saavutatakse täielik ravivastus, võib vastavalt individuaalsele kliinilisele hinnangule kaaluda ravi jätkamist suurema annusega: 8 mg/kg iga 8 nädala järel.
English: Pull the plunger of the syringe all the way down to the 1.0 ml mark, filling the syringe with air. Insert the syringe needle into the vial of Ilaris solution through the centre of the rubber stopper.
Estonian: - Suruge lahuse võtmise nõel läbi kummikorgi keskosa Ilarise lahust sisaldavasse viaali.
English: Each ml of solution contains 150 mg canakinumab.
Estonian: Üks ml lahust sisaldab 150 mg kanakinumabi.
English: 9/l) and transient decreases in platelet counts were observed at a higher incidence (12.7%) with canakinumab in the active-controlled clinical studies versus the comparator (7.7%) in gouty arthritis patients.
Estonian: 9/l) ja mööduvaid langusi kanakinumabiga rohkem (12,7%) kui võrdlusravimiga
English: There were 80 paediatric CAPS patients (2-17 years of age) who received canakinumab in the interventional studies.
Estonian: Sekkumisuuringutes osales 80 CAPS diagnoosiga last (vanuses 2...17 aastat), keda raviti kanakinumabiga.
English: Ilaris 150 mg/ml solution for injection canakinumab
Estonian: Ilaris 150 mg/ml süstelahus kanakinumab (canakinumabum)
English: Tell your doctor or your child's doctor immediately if you notice any of these symptoms.
Estonian: Kui märkate mistahes nendest loetletud sümptomitest, rääkige sellest otsekohe oma arstile või oma lapse arstile.
English: Renal impairment
Estonian: Podagra ravi
English: Avoid injecting into a vein.
Estonian: Vältige veeni süstimist.
English: Gastrointestinal disorders Very common Upper abdominal pain Uncommon Gastro-oesophageal reflux disease Skin and subcutaneous tissue disorders Very common Injection site reaction Musculoskeletal and connective tissue disorders Very common Arthralgia Common
Estonian: Gastroösofageaalne reflukshaigus Naha ja nahaaluskoe kahjustused Väga sage
English: Treatment with canakinumab resulted in clinically relevant improvements in patients' physical function and quality of life.
Estonian: Uuringute G2305 ja G2301 tervise ja elukvaliteediga seonduvad tulemusnäitajad Kanakinumabi ravi tulemusel paranes kliiniliselt oluliselt patsientide füüsiline seisund ja elukvaliteet.